AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity

RecruitingNAAges 12 Years - anyAllCentre Hospitalier Universitaire de Saint Etienne
💬

In plain words

What the trial is, and whether it could suit you

Wilson's disease is a genetic disorder, resulting from an anomaly present on the ATP7B gene located on chromosome 13, causing a progressive accumulation of copper in various organs such as the liver, nervous system and cornea, leading to various hepatic and neurological disorders and a systemic evolution. Currently, the first-line treatment for this disease is D-Penicillamine, which acts by chelation and promotes copper excretion through the urine. Unfortunately, this treatment also has significant side-effects, particularly on the skin. However, the pathogenesis of elastopathy in patients with Wilson's disease has yet to be fully characterized, and needs to be better understood in order to adapt the therapeutic strategy. A silicon mold will be made on Wilson's disease patients, enabling the skin micro-relief to be shaped, and analyzed by confocal laser in comparison with the skin of h

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: Diseased patients : * Patient over 12 years old * Patient with Wilson's disease confirmed by genetic analysis * Patient followed up in the Wilson's Disease Reference Center for his care * Patient treated with D-Penicillamine * Patient with no other known elastic tissue pathology Healthy volunteers : * Patient over 12 years old * Patient followed up in the dermatology department of St Etienne University Hospital * Patient matched on sex and age with a patient from the "Wilson's disease" group * Patient with no elastic tissue pathology All patients : * Patient affiliated to a national social security * Patient with written informed consent Exclusion Criteria: All patients: * Patient not taking a treatment (at investigator's discretion) that may modify skin elasticity * Patient with pathological lesion(s) on forearm or cheek * Patient with a potentially active/rejuvenative forearm or cheek treatment * Patient having applied cream and/or make-up to the areas to be molded (forearm and cheek) * Patient under guardianship * Patient unable to follow study procedures * Pregnant or breast-feeding women
💊

What it tests

  • Preparation of forearm molds with SILFLO® silicone
📍

Where

2 sites
Hospices Civils de Lyon
Bron, France
Hôpital Nord CHU de Saint-Étienne
Saint-Etienne, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy